Breaking News
June 18, 2018 - AHA: Family Perseveres After Losing Father to Heart Attack
June 18, 2018 - Oral propranolol seems safe for infantile hemangioma
June 18, 2018 - New study gives explanation for food’s prominence in memory
June 18, 2018 - First photoactive drug to fight Parkinson’s disease
June 18, 2018 - Patient’s self-evaluation of personality disorders not as far off as previously perceived
June 18, 2018 - Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis
June 18, 2018 - Vitamin B3 has a positive effect on damaged nerve cells in Parkinson’s patients
June 17, 2018 - Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
June 17, 2018 - Bid to beat obesity focuses on fat that keeps us warm
June 17, 2018 - Work Stress May Increase Risk of Developing Atrial Fibrillation
June 17, 2018 - New Zealand’s secret recipe for active school travel: The neighborhood built environment
June 17, 2018 - New Medscape report reveals sexual harassment rate of physicians
June 17, 2018 - Surgical Blood Transfusions Tied to Clot Risk
June 17, 2018 - CDC chief makes $375K, far exceeding his predecessors’ pay
June 17, 2018 - Education linked to higher risk of short-sightedness
June 17, 2018 - Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
June 17, 2018 - UA registers a more customised multifocal lens to correct presbyopia
June 17, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
June 17, 2018 - Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort
June 17, 2018 - Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis
June 17, 2018 - Radiation Therapy for Cancer – National Cancer Institute
June 17, 2018 - Technology could help pregnant women detect health complications
June 17, 2018 - Study finds drop in frequent use of ED after Affordable Care Act
June 17, 2018 - Do Antipsychotic Meds for Kids Raise Diabetes Risk?
June 17, 2018 - New light shed on mechanisms of paediatric epilepsy
June 17, 2018 - People who deeply grasp the pain or happiness of others also process music differently in the brain
June 16, 2018 - Scientists discover how cancer-targeting ‘Natural Killer’ cells are fueled in the body
June 16, 2018 - New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2018 - Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
June 16, 2018 - Ibuprofen, acetaminophen more effective than opioids in treating dental pain
June 16, 2018 - Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
June 16, 2018 - Price competition for generic drugs linked to increase in manufacturing-related recalls
June 16, 2018 - Researchers develop biomimetic nanosystem to deliver therapeutic proteins to target tumors
June 16, 2018 - Negative Pressure Wound Tx No Benefit for Lower Limb Open Fx
June 16, 2018 - Should I Get Screened for Prostate Cancer?
June 16, 2018 - Biochemist, physicist team to see antibacterial TCS deform mitochondria
June 16, 2018 - New 2D Superresolution mode for ZEISS Airyscan offers higher resolution in live cell imaging
June 16, 2018 - Money Spurs Those With Heart Disease to Step Lively
June 16, 2018 - Lower Dose of Prostate Cancer Drug with Food
June 16, 2018 - New findings demonstrate how the food we eat affects biochemical signals in the gut
June 16, 2018 - Scientists develop method to determine metabolic activity of neural networks
June 16, 2018 - Topical gel may lower breast cancer risk in women with dense breast tissue
June 16, 2018 - Research team diagnoses asthma with nasal brush test
June 16, 2018 - Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
June 16, 2018 - Novel PET imaging noninvasively pinpoints colitis inflammation
June 16, 2018 - New clinical trial of MS drug will be first to recognize needs of wheelchair users
June 16, 2018 - Evoke Announces FDA Submission of New Drug Application for Gimoti
June 16, 2018 - New study links gray hair with immune system activity and viral infection
June 16, 2018 - Various E-cigarette flavorings may increase risk of cardiovascular disease
June 16, 2018 - Research sheds light on pathways involved in transmitting itch sensations from skin to brain
June 16, 2018 - Eminent biologist resigns over allegations of gender discrimination and sexual harassment
June 16, 2018 - Consuming sugary soft drinks can make you fat
June 16, 2018 - CDC: Preterm Births Increased in United States During 2014-2016
June 16, 2018 - Adolescents with hay fever have higher rates of anxiety and depression, lower resistance to stress
June 16, 2018 - Metabolic process providing energy to heart muscle fails to mature in babies with hypertrophy
June 16, 2018 - TU Graz researchers manipulate enzymes to build ring-shaped molecular structures
June 16, 2018 - Looking Good! Plastic Surgery for Men Surges
June 16, 2018 - Discovery of how HIV hedges its bets opens the door to new therapies
June 15, 2018 - Researchers evaluate left ventricular systolic function after pulmonary valve replacement
June 15, 2018 - New resource launched based on first-hand experiences of premature baby loss
June 15, 2018 - About Teen Pregnancy | Teen Pregnancy | Reproductive Health
June 15, 2018 - In southern Mozambique, one out of three people diagnosed with HIV do not disclose their status
June 15, 2018 - Researchers discover genomic characteristics that define testicular germ cell cancer
June 15, 2018 - Engineers create first 3D computer model to show breast duct development
June 15, 2018 - ANU scientists invent new system that could help crack down on illegal drug trade
June 15, 2018 - Study shows remarkable plasticity of the brain in finding work-arounds after catastrophic injuries
June 15, 2018 - Study finds higher response to anti-PD1 immunotherapy in older melanoma patients
June 15, 2018 - New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 15, 2018 - Smoking, lack of exercise linked to early death after divorce
June 15, 2018 - Researchers identify gene enhancer that affects sex determination
June 15, 2018 - New collaboration integrates Intabio’s Blaze solution with Bruker’s mass spectrometers
June 15, 2018 - Blood samples can be used to uncover genetic secrets inside the brain
June 15, 2018 - Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
June 15, 2018 - Can you rely on the drugs that your doctor prescribes?
June 15, 2018 - WHO: Paraguay achieves malaria-free status
June 15, 2018 - Investigating Enamel Nanostructure with Nanoindentation
June 15, 2018 - FDA Approves Moxidectin for the Treatment of River Blindness
June 15, 2018 - Researchers discover cell structure that plays a role in epigenetic inheritance
June 15, 2018 - Study shows how using service dogs may provide physiological benefits to veterans with PTSD
June 15, 2018 - New chemical solution could reduce chances of infection associated with root canal work
Triple Therapy Improves PFS in Certain Breast Ca Patients

Triple Therapy Improves PFS in Certain Breast Ca Patients

image_pdfDownload PDFimage_print

Action Points

  • Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib (Tykerb) and trastuzumab (Herceptin) + an aromatase inhibitor (AI) improved progression-free survival (PFS) versus single HER2 blockade in HER2-positive/hormone receptor (HR)-positive metastatic breast cancer.
  • Note that HER2–positive breast cancer (BC) constitutes approximately 20% to 25% of BC and is associated with poor prognosis,and approximately 50% of HER2-positive BCs are HR-positive, so HER2-positive/HR-positive represent roughly 10% of all BCs.

Targeting HER2 with two agents — lapatinib (Tykerb) and trastuzumab (Herceptin) — and adding an aromatase inhibitor (AI) significantly improved progression-free survival (PFS) compared to trastuzumab/AI in patients with HER2-positive and hormone receptor-positive metastatic breast cancer, researchers found.

Results from the large, randomized, phase III ALTERNATIVE trial demonstrated that the combination of lapatinib/trastuzumab/AI provided a clinically meaningful prolongation of PFS compared with trastuzumab/AI with a median PFS of 11.0 versus 5.7 months, respectively, according to Stephen R.D. Johnston, MA, PhD, of The Royal Marsden NHS Foundation Trust in London, and colleagues.

This represented a statistically significant 38% reduction in the risk of disease progression (hazard ratio [HR] 0.62; P=0.0064) in patients not suitable for chemotherapy, the study authors reported online in the Journal of Clinical Oncology. Lapatinib/trastuzumab/AI was also relatively well tolerated compared with trastuzumab/AI.

These findings indicate that patients with HER2-positive/HR-positive MBC who are not candidates for chemotherapy can be adequately treated with dual HER2 blockade plus an AI, Johnston and colleagues emphasized. “Although survival data were immature, there was also a trend in favor of the dual-blockade treatment (median 46.0 versus 40.0 months),” they wrote.

The PFS benefit of lapatinib/trastuzumab/AI compared with trastuzumab/AI was consistent across patient subgroups. The overall response rate (ORR) and clinical benefit rate (CBR) also favored the lapatinib/trastuzumab/AI combination over trastuzumab/AI (ORR 31.7% versus 13.7%, and CBR 41% versus 31%, respectively).

“Dual HER2 blockade enhances clinical benefit versus single HER2 blockade,” the study authors noted. “The use of dual anti-HER2 blockade represents a potential strategy to further improve the outcome of these patients,” Johnston and colleagues added.

The ALTERNATIVE trial enrolled 355 postmenopausal women from 112 sites in 29 countries. All patients had received prior endocrine therapy and experienced disease progression after prior neo(adjuvant)/first-line trastuzumab plus chemotherapy. Patients were randomly assigned 1:1:1 to lapatinib/trastuzumab/AI, trastuzumab/AI, or lapatinib/AI.

In the lapatinib/trastuzumab/AI arm, patients took 1,000 mg/day oral lapatinib. In the lapatinib/AI arm, patients took 1,500 mg/day. In both trastuzumab arms, patients received an IV loading dose of 8 mg/kg trastuzumab followed by a maintenance dose of 6 mg/kg every 3 weeks. Oral AIs included letrozole (Femara; 2.5 mg/day), antinuclear antibodies (1 mg/day), or exemestane (Aromasin; 25 mg/day).

The median PFS with lapatinib/AI versus trastuzumab/AI was 8.3 versus 5.7 months (HR 0.71; P=0.0361).

Common adverse events were seen in lapatinib/trastuzumab/AI; trastuzumab/AI; and lapatinib/AI, respectively, and included:

  • Diarrhea (69%, 9%, and 51%)
  • Rash (36%, 2%, and 28%)
  • Nausea (22%, 9%, and 22%)
  • Paronychia (30%, 0%, and 15%)

Frequency of adverse events, mostly grade 1 or 2, was 92% in the two lapatinib arms and 74% in the trastuzumab arm. Serious AEs were reported across the three study groups, with discontinuation lowest in the lapatinib/trastuzumab/AI arm (3%) compared to the trastuzumab/AI (6%) and lapatinib/AI (9%) arms.

Other studies looking at HER2 blockade have been conducted in different patient populations, so “cross-trial comparisons need to be interpreted with caution,” the study authors warned. Although the PFS outcome in ALTERNATIVE lines up with results from other studies, there are a limited number of trials designed for patients with HER2-positive/HR-positive metastatic breast cancer, they pointed out.

In the phase II PERTAIN study of locally advanced or metastatic hormone receptor-positive HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab and an AI in the first-line setting significantly improved PFS by 3 months. The median PFS was 18.9 months with pertuzumab, trastuzumab and endocrine therapy compared to 15.80 months with trastuzumab plus endocrine therapy.

However, only 77% of patients were trastuzumab-naive and 55% of patients had received induction chemotherapy in this first-line setting, the ALTERNATIVE study authors noted.

The rationale for PERTAIN came from the TAnDEM study, which showed that adding trastuzumab to anastrozole (Arimidex) significantly improved PFS over anastrozole alone. The CLEOPATRA study also demonstrated improved PFS and OS with the addition of pertuzumab to trastuzumab plus docetaxel.

These findings contrast the lack of benefit observed with lapatinib in the adjuvant setting in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial, Johnston and colleagues pointed out. In addition, the APHINITY trial demonstrated only a modest benefit with pertuzumab.

“This discrepancy may be the result, at least in part, of the excellent outcome with adjuvant single HER2 blockade with TRAS, making the demonstration of additional benefit with dual blockade harder. Dual HER2 blockade may benefit only a small subset of high-risk patients,” they suggested.

Similarly, results from an earlier international trial showed that adjuvant therapy with two HER2-targeted drugs failed to improve disease-free survival in early breast cancer compared with trastuzumab monotherapy. Concurrent administration of lapatinib and trastuzumab resulted in a nonsignificant 16% reduction in DFS compared with trastuzumab alone.

However, in a nonrandomized phase II study, the combination of lapatinib and trastuzumab was effective and well-tolerated in patients with HER2+ breast cancer who had received up to two lines of therapy for advanced disease. The study also showed that metabolic imaging appeared to be helpful for selecting poor responders in advance, thus sparing them the toxicity of chemotherapy.

Original funding for the ALTERNATIVE study was provided by GlaxoSmithKline. As of March 2, 2015, lapatinib was acquired by Novartis, the current sponsor of this study. Johnston reported relationships with Novartis, Eli Lilly, AstraZeneca, OBI Pharma, Puma Biotechnology, and Pfizer. A number of study co-authors also reported relationships with industry, including GlaxoSmithKline and Novartis.

2017-12-28T14:30:00-0500

Tagged with:

About author

Related Articles